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B108 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5METHODS Weprospectively enrolled STEMI patients undergoing primary
PCI, whom were treated with clopidogrel (600 mg loading and 75 mg QD
maintenance: n ¼ 105) or ticagrelor (180 mg loading and 90 mg bid main-
tenance: n ¼ 64) on top of aspirin. We serially measured platelet reactivity
(usingVerifyNowassay: pre-PCI, post-PCI, and 1-month follow-up), hs-CRP
(pre-PCI, post-PCI, and 1-month follow-up), ﬁbrinogen (pre-PCI and 1-
month follow-up), vascular function (using brachial-ankle pulse wave ve-
locity [baPWV]: post-PCI and 1-month follow-up) and LV remodeling index
(using transthoracic echocardiography: post-PCI and 1-month follow-up).
RESULTS Baseline demographics and laboratorymeasurementswerewell
balanced between the treatments. Compared with clopidogrel treatment,
ticagrelor treatment showed the lower levels of platelet reactivity frompre-
PCI phase (all p values  0.034) (Table). At 1-month follow-up, ticagrelor
treatment sufﬁciently inhibited ADP-induced platelet reactivity (mostly
less than 100 PRU). However, there were no differences in terms with hs-
CRP level, baPWV and LV remodeling index between the treatments.
Interestingly, ticagrelor versus clopidogrel reduced thrombin-mediated
platelet reactivity (224  33 vs. 240  46 BASE; p ¼ 0.030) and enhanced
ﬁbrinogen level (400  104 vs. 360  100 mg/dL; p ¼ 0.027).Variables Clopidogrel Ticagrelor P valueADP-PRPRUpre-PCI 273  64 240  67 0.003PRUpost-PCI 208  78 55  60 < 0.001PRU1-month 169  64 24  37 < 0.001Thrombin-PRBASEpre-PCI 247  56 217  41 0.001BASEpost-PCI 276  52 256  61 0.034BASE1-month 240  46 224  33 0.030Inﬂammation (mg/L) (mg/L)Hs-CRPpre-PCI 7.9  22.2 4.0  9.8 0.193Hs-CRPpost-PCI 40.3  50.7 29.6  47.0 0.251Hs-CRP1-month 4.9  15.9 3.4  5.9 0.505Coagulation (mg/dL) (mg/dL)Fibrinogenpre-PCI 334  100 318  77 0.281Fibrinogen1-month 360  100 400  104 0.027Vascular function (cm/s) (cm/s)baPWVpost-PCI 1620  438 1623  498 0.970baPWV1-month 1479  324 1516  381 0.571LV remodeling index (%) -2.7  27.3 -6.0  23.8 0.609CONCLUSIONS After the short-term treatment with ticagrelor versus
clopidogrel, its strong inhibition of platelet activation is not associ-
ated with inﬂammation, vascular function and LV remodeling process
in STEMI patients. Beneﬁcial role of ticagrelor needs to be evaluated
in randomized clinical trials after long-term treatment.
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BACKGROUND Successful percutaneous coronary intervention (PCI)
of the occluded infarct-related artery (IRA) in latecomers may improve
long-term survival mainly by reducing left ventricular remodeling. It is
not clear whether inhibition of renin-angiotensin system (RAS) brings
additional better clinical outcomes in this speciﬁc population subset.
METHODS Between January 2008 and June 2013, 669 latecomer pa-
tients with acute myocardial infarction (MI) (66.2  12.1 years old,
71.0% males) in Korea Acute Myocardial Infarction Registry (KAMIR)who underwent a successful PCI were enrolled. The study population
underwent a successful PCI for a totally occluded IRA. They were
divided into two groups according to whether they were prescribed
RAS inhibitors at the time of discharge or not: group I (RAS inhibition,
n¼556), and group II (No RAS inhibition, n¼113).
RESULTS During the one-year follow-up, major adverse cardiac
events (MACE), which consist of cardiac death and MI, occurred in 71
patients (10.6%). There were signiﬁcantly reduced incidences of
MACE in the group I [hazard ratio (HR) ¼ 0.34, 95% CI (conﬁdence
interval) 0.199 - 0.588, p¼0.001]. In subgroup analyses, RAS inhibition
was beneﬁcial in patients with male gender, history of hypertension
or diabetes mellitus, and even in patients with left ventricular ejection
fraction (LVEF) 40%. In the baseline and follow-up echocardio-
graphic data, beneﬁt in changes of LVEF and left ventricular end-
systolic volume was noted in the group I.
Comparison between baseline and follow-up echocardiographic data.VariableGroup I
(RAS inhibition,
n[556)Group II
(no RAS inhibition,
n[113) p valueBaselineLVEF (%) 51.9  10.6 51.3  14.1 0.595LVESV (ml) 57.5  17.6 58.2  21.8 0.678LVEDV (ml) 118.9  19.7 118.6  18.9 0.889Follow-upTime interval from
baseline exam
(days)117  58.3 121  62.5 0.328LVEF (%) 55.6  11.1 50.7  11.9 <0.001LVESV (ml) 51.6  17.8 59.3  21.2 <0.001LVEDV (ml) 115.1  18.3 118.9  19.2 0.048% change from the baseline
examLVEF (%) 9.4  24.9 2.6  23.0 0.007LVESV (ml) -7.5  28.3 7.2  32.3 <0.001LVEDV (ml) -1.3  19.3 2.4  22.8 0.071CONCLUSIONS In latecomers with acute MI, RAS inhibition improved
long-term clinical outcomes after a successful PCI, even in patients
with low risk who had relatively preserved LVEF.
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